Table 3 PRO clinical trials characteristics
Trial characteristics | Number of trials, (%) |
|---|---|
Trial phase | |
 I | 0 |
 I/II | 1 (1.4) |
 II | 1 (1.4) |
 III | 24 (34) |
 Other | 3 (5.7) |
 Not specified | 40 (57) |
Leading study centre | |
 UK | 62 (89) |
 International | 7 (11) |
Trial design | |
 International multicentre study | 21(30) |
PRO outcome | |
 Primary outcome | 17 (24) |
 Secondary outcome | 35 (50) |
 Both | 11 (15) |
PRO measures used | |
 SF-36 | 17 (24) |
 EQ-5D | 12 (17) |
 HADS | 9 (13) |
 VAS | 9 (13) |
 EORTC QLQ-C30 | 3 (4) |
 Other | 70a |